Compugen reports Q1 earnings, strong cash position, partnerships, pipeline advancements, despite financial losses

From Investing.com: 2024-05-20 18:23:04

Compugen Ltd. (NASDAQ: CGEN) reported Q1 2024 financial results, with $2.6 million in revenue and a net loss of $7.3 million. The company has a strong cash position of $101.3 million, ensuring a cash runway into 2027. Compugen highlighted successful AI-driven drug target transitions and upcoming data presentations at ASCO. Partnership developments with Gilead and AstraZeneca are key highlights, with plans for new Phase 3 trials and IND submissions in the pipeline. The company is focused on platinum-resistant ovarian cancer and exploring combination treatments. Compugen is confident in its pipeline’s long-term value creation potential, despite reported financial losses in Q1 2024. Data metrics from InvestingPro reveal Compugen’s market cap of $155.78 million and gross profit margin of 94.01%. The company has more cash than debt, but analysts do not expect profitability this year. coupon code PRONEWS24 offers 10% off InvestingPro subscription for comprehensive insights into Compugen’s financial health and market potential. Compugen’s strategic AI-focused approach in drug discovery and partnerships position them in the biotech industry, despite financial losses reported in Q1 2024. Compugen’s market cap, gross profit margin, cash balance, and profitability outlook provide critical insights for potential investors. Considering Compugen’s strong cash position and pipeline advancements, investors can assess the company’s long-term growth potential and market performance with the help of InvestingPro’s data metrics and analysis tools.



Read more at Investing.com: Compugen outlines progress and plans in Q1 2024 earnings By Investing.com